A multicenter randomized trial evaluating the possible benefit of androgens during post
remission therapy in an attempt to improve the outcome of AML in older patients.All patients
received the ICL regimen as induction and were randomized to receive, after achieving CR or
PR, a maintenance therapy including or not androgens. Patients randomized with androgens
additionally received 10 to 20 mg according to body weigh of norethandrolone daily for up to
2 years